Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Topic: Immunotherapy for Cancer

A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 31 Dec 2022

Guest Editor(s)

  • Prof. Steven N. Fiering
    Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth.

    Website | E-mail

Special Issue Introduction

The establishment of T-cell immune checkpoint inhibition (ICI) as a standard immune-based cancer treatment started a revolution in cancer treatment that manipulates the patient’s immune system to eliminate tumors. It started with the acceptance that tumors are recognized by the immune system, following over 100 years of debate. This understanding was solidified by learning that some forms of cell death are immunogenic, and some standard cytotoxic cancer drugs were exploiting the immune system to recognize immunogenic cell death caused by the drug and eliminate cancer cells by immune attack. Now as the use of checkpoint blocking antibodies expands, it is clear that ICI by itself is not sufficient, and many labs are developing other immune-based therapies. These include adoptive immune cell therapy, therapeutic vaccines, oncolytic and immune stimulating microorganisms and other approaches. These can be used either systemically or by direct injection into recognized tumors with the expectation that this treatment (in situ vaccination) will expand systemic antitumor immunity. The current focus is on combining immune therapy options to get better response rates. Other important areas are identifying immune mechanisms, biomarkers of response during treatment or prior to treatment. It will be a long road, but we may be at the “end of the beginning” as we move toward combinatorial immunotherapy.

Submission Deadline

31 Dec 2022

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Dec 2022
Contacts: Carl Zhou, Assistant Editor,

Published Articles

This special issue is now open for submission.
© 2016-2022 OAE Publishing Inc., except certain content provided by third parties